Immunovia (IMMNOV) Q3 2024 earnings summary

Executive summary

• Achieved key milestones in next-generation pancreatic cancer test development, completing discovery, model development, and analytical validation, with clinical validation to finish by December 2024.

• Next-generation test demonstrated 85% sensitivity and 98% specificity, outperforming CA19-9 by 20 percentage points in sensitivity at equivalent specificity.

• Transitioning from R&D to commercial phase in 2025, with a planned U.S. launch in H2 2025 and focus on strategic partnerships.

• Revenue for Q3 2024 was SEK 235k, consisting solely of royalties, down from SEK 488k in Q3 2023.

• Net result for Q3 2024 was SEK -51.1m, impacted by unrealized currency effects and a one-time provision for loss contracts.

Financial highlights

• Q3 2024 operating expenses were just over SEK 30 million, a 20% reduction year-over-year, with headcount costs down over 60%.

• Q3 cash burn totaled SEK 21.2 million, down 40% from last year; cash balance at quarter-end was SEK 54.2 million.

• Rights issue in Q3 2024 raised SEK 52.4 million net, with 91% subscription, exceeding expectations.

• R&D expenses in Q3 2024 were SEK 9.1 million, 29% of total operating costs.

• Personnel costs decreased to SEK 6.5 million in Q3 2024 from SEK 17.1 million in Q3 2023.

Outlook and guidance

• Clinical validation of the next-generation test is the main focus for Q4 2024, with results expected in December.

• Cash burn expected to rise in Q4 to SEK 8–10 million per month due to increased R&D activity.

• OpEx will shift from R&D to studies supporting reimbursement and commercialization in 2025.

• U.S. test launch planned for H2 2025 as a laboratory-developed test, with initial revenue limited to patient payments; payer reimbursement expected in 2026.

• Additional clinical studies required for insurance reimbursement will be conducted in 2025.